Pharma channel feed

FDA OKs an in­haled ver­sion of smok­ing ces­sa­tion drug Chan­tix — for a com­mon eye dis­ease

4 years ago
FDA+

Es­pe­ri­on gets out the bud­get ax, chop­ping 170 staffers as its big drug launch sput­ters

4 years ago
People

Boehringer nabs FDA's first in­ter­change­abil­i­ty des­ig­na­tion for its Hu­mi­ra com­peti­tor — but will it mat­ter?

4 years ago
FDA+

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

4 years ago
FDA+

As suits mount, J&J spins out talc li­a­bil­i­ties in­to Chap­ter 11 us­ing 'Texas two-step' ma­neu­ver

4 years ago

Mer­ck carves out path in first-line ad­vanced cer­vi­cal can­cer with new FDA win for Keytru­da jug­ger­naut

4 years ago
FDA+

Spurned by the FDA, Arde­lyx ex­ecs grab bonus­es to stay on while ax­ing near­ly two-thirds of re­main­ing staff

4 years ago
People

Eli Lil­ly bags FDA nod for Verzenio in ear­ly breast can­cer, but a con­tro­ver­sial di­ag­nos­tic could dog its roll­out

4 years ago
FDA+

As TRIPS coun­cil meets, the IP waiv­er for vac­cines is on life sup­port ahead of a De­cem­ber dead­line

4 years ago
Coronavirus

As Con­gress bat­tles over gov­ern­ment drug price ne­go­ti­a­tion, new poll finds strong sup­port on both sides of the aisle

4 years ago

Post-split GSK to ex­it mar­quee world HQ, blue­print­ing small­er cor­po­rate digs

4 years ago

FDA's an­timi­cro­bial ad­comm unan­i­mous­ly backs Takeda's drug for post-trans­plant cy­tomegalovirus

4 years ago
FDA+

A short-sell at­tack sends Ginkgo's share price spin­ning, un­der­scor­ing in­vestors' con­cerns over syn­bio field

4 years ago

FDA of­fers sup­port for Takeda's po­ten­tial cy­tomegalovirus drug ahead of ad­comm

4 years ago
FDA+

Af­ter a brief stint in the top can­cer re­search spot at Gilead, Va­le­ria Fan­tin jumps over to Sanofi

4 years ago
People

Glax­o­SmithK­line aban­don­ing icon­ic US HQ space in a shift in­spired by the new nor­mal

4 years ago

Feds ac­cuse As­traZeneca of un­der­pay­ing 318 fe­male and His­pan­ic em­ploy­ees

4 years ago
People

Gang of 7: Boehringer joins group of com­pa­nies tar­get­ed over drug dis­count pro­gram

4 years ago

Three gener­ic firms shell out $447M more to set­tle fed­er­al price fix­ing al­le­ga­tions

4 years ago

Pfiz­er los­es close­ly watched court case on kick­backs and sub­si­diz­ing drugs

4 years ago

An FDA mis­take sig­nals like­ly ap­proval for first ther­a­py for chil­dren born with­out a thy­mus

4 years ago
FDA+

Unit­ed Ther­a­peu­tics tran­si­tions to pub­lic ben­e­fit cor­po­ra­tion more than 20+ years af­ter IPO

4 years ago

Avoro Cap­i­tal, the deal killer be­hind the Seagen-Im­munomedics blowup, has turned its eyes on Mer­ck­'s Ac­celeron buy­out

4 years ago

Cat­a­lyst wins re­ver­sal in or­phan ex­clu­siv­i­ty court bat­tle with FDA

4 years ago
FDA+
First page Previous page 231232233234235236237 Next page Last page
A service from the Financial Times